



AVI BioPharma to Present at UBS Global Specialty Pharmaceuticals Conference

4/21/06

PORTLAND, Ore., Apr 21, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Monday, April 24, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Specialty Pharmaceuticals Conference to be held at the Grand Hyatt New York. The presentation will take place at 12 p.m. EDT in Ballroom E.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at <http://www.avibio.com>.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

SOURCE: AVI BioPharma, Inc.

AVI BioPharma, Inc.

Michael Hubbard, 503-227-0554

hubbard@avibio.com

or

Lippert/Heilshorn & Associates Inc. (Investor Contacts)

Jody Cain, 310-691-7100

jcain@lhai.com

or

Brandi Floberg, 310-691-7100

bfloberg@lhai.com

or

Waggener Edstrom Worldwide (Press Contact)

Bioscience and Healthcare Practice

Jenny Moede, 503-443-7507

jmoede@waggeneredstrom.com